Natural, youthful skin
restored for
GLP-1 patients.

GLP-1 receptor agonists (semaglutide, tirzepatide) drive systemic fat loss that disproportionately affects the dWAT layer^[11]Ref 11Ridha Z et al. Decoding the Implications of GLP-1 Receptor Agonists on Accelerated Facial and Skin Aging. Aesthet Surg J. 2024;44(11):NP809–NP818. PMID 38874170 — Documents facial fat compartment depletion in GLP-1 patients; identifies dWAT loss as distinct from subcutaneous volume loss. — the adipocyte stratum within the reticular dermis that provides mechanical support, turgor, and structural depth to the overlying skin.^[1,8]Ref 1,8Driskell RR et al. Defining dermal adipose tissue. Exp Dermatol. 2014;23:629–631. PMC4282701 — Established dWAT nomenclature; demonstrated distinct developmental origin shared with dermal fibroblasts, not subcutaneous adipose.

Kruglikov IL, Scherer PE. Skin aging as a mechanical phenomenon. Nutr Healthy Aging. 2018;4:291–307. — Demonstrated skin stiffness in mice is inversely correlated with dWAT thickness; dWAT mechanically interacts with dermis and contributes to wrinkle formation. When dWAT atrophies, the facial fat pads (malar, submalar, buccal, temporal) lose their structural foundation. The result is hollowing, skin laxity, and a compromised injection substrate.

HA filler can help address areas of fat loss and restore volume for GLP-1 patients — many providers and patients are satisfied with the results. The key distinction is what it addresses. Filler restores surface volume. Adipose tissue plays a broader role in skin health — supporting structural integrity, housing stem cells, and contributing to fibroblast signaling. Filler does not address those functions. For patients with significant structural depletion, Lipoderma targets the tissue layer itself rather than the surface appearance.

Sculptra addresses this by biostimulating collagen — but collagen is not the deficit. The deficit is adipocytes. Sculptra does not restore the dWAT adipocyte population, which means the structural substrate remains absent regardless of collagen stimulation.^[3]Ref 3Kruglikov IL, Scherer PE. Skin aging: are adipocytes the next target? Aging (Albany NY). 2016;8:1457–1469. PMC4993342 — dWAT modulates fibroblast activity via paracrine signaling; chronic depletion correlates with fibrotic replacement and skin aging.

The clinical rationale is mechanistically straightforward: restore the dWAT adipose scaffold first, then place HA filler into tissue that has the depth and structural support to retain it correctly.

Step 1 — Lipoderma: Injected into depleted fat pad compartments (malar, submalar, temporal, buccal). Reintroduces real adipocytes within an ECM scaffold — the biological architecture dWAT is composed of. Creates the structural foundation for subsequent filler placement. Integration timeline per Britecyte IFU.

Sequencing considerations: Lipoderma may be used alongside or before other treatments depending on the indication and physician preference. Dr. Chernoff's approach in body applications typically uses CaHA first, followed by Lipoderma approximately one month later. For facial GLP-1 restoration, sequencing should reflect clinical judgment and the full IFU. Present as a protocol with strong mechanistic rationale — outcomes from controlled trials are forthcoming.

What is clinically established: Lipoderma's ~90/10 adipocyte/ECM composition confirmed by Britecyte characterization. No adverse events in either published clinical pilot. Fat pad thickness increase at 12 weeks: 9/10 treated sites, mean +0.21 cm (65% improvement) in the metatarsalgia series^[10]Ref 10Schoenhaus Gold S et al. Injectable adipose tissue allograft for plantar fat pad atrophy. Plast Reconstr Surg Glob Open. 2025. PMC12674145 — n=9 patients/10 feet; 9/10 sites showed increased fat pad thickness at 12 weeks; mean +0.21 cm (65% improvement); FADI improved 66→84. — a structurally analogous fat pad atrophy model.

Dr. William Gregory Chernoff (BSc, MD, FRCSC — triple board-certified facial plastic and reconstructive surgeon, 30+ years experience) conducted a six-month IRB-approved proof-of-concept study (IRB ICSS-2021-011) evaluating Lipoderma across multiple facial and body sites in patients with adipose loss secondary to GLP-1 therapy.

Study cohort: 12 patients (8 female, 4 male), ages 32–76 (mean 42 years). All patients had been on GLP-1 therapy for a minimum of one year. Implantation volumes ranged from 1cc to 10cc per session. Patients were followed daily for one week, weekly for one month, and monthly through the six-month endpoint.

Sites treated: Malar/submalar region, nasolabial and melolabial folds, nasal dorsum, lower third of face, pre-jowl sulcus, tear trough, upper eyelid, hands, breasts, buttocks, and legs. Lipoderma was also incorporated into multimodal wound and scar management protocols as a scaffold for tissue repair.

Outcomes: Quantificare 3D imaging demonstrated measurable improvement in skin tone, texture, and overall skin quality when Lipoderma was implanted in the immediate subdermal plane. Where volumization was the primary goal, Quantificare analysis showed successful early outcomes with sustained volume retention through the six-month endpoint. Improvement was particularly observed in atrophic scars, striae, and cellulite, where restoration of structural adipose support contributed to improvements in tissue quality.

Safety: No allergic reactions, hypersensitivity responses, or other adverse events attributable to Lipoderma implantation were observed at any study timepoint across all 12 patients.^[12]Ref 12Chernoff WG. Utilization of a Human Adipose Tissue Allograft (hATA) for the Restoration of Dermal Adipose in Aesthetic Plastic and Reconstructive Surgery. White Paper, 2025. IRB ICSS-2021-011 — n=12 GLP-1 patients (all ≥1 year on therapy); 6-month follow-up; 0 adverse events; Quantificare 3D imaging showed measurable skin quality improvement.

In select cases within the Chernoff series, hybrid strategies combining Lipoderma with hyperdilute calcium hydroxyapatite (CaHA) were employed for larger-area body volumization — including medial thigh (58-year-old female, 6-month follow-up), gluteal region (54-year-old female, 6-month follow-up), and posterior gluteal region across two sessions (74-year-old female, 12-month follow-up). These approaches appeared to enhance clinical effectiveness relative to either product alone.

The mechanistic rationale: Lipoderma restores the adipose scaffold (adipocytes + ECM) at the subdermal plane; hyperdilute CaHA provides structural lift and biostimulation in the deeper tissue plane. The two products address different tissue layers — making the combination genuinely complementary rather than redundant.

Chernoff's conclusion is direct: "By restoring the structural adipose layer beneath the dermis, [Lipoderma] offers a like-for-like solution for areas where native adipose tissue has been diminished or lost... This restoration-based strategy may represent an important shift in aesthetic and reconstructive medicine — from simply replacing lost volume to rebuilding the structural tissue layers that support skin health."

Best-fit patients: Active or recently stabilised GLP-1 users (semaglutide, tirzepatide) presenting with facial hollowing, skin laxity, or reduced skin quality — particularly in the malar, temporal, and periorbital regions. Post-bariatric patients with similar facial fat loss. Patients where HA filler alone has underperformed or required unusually frequent retreatment.

Timing consideration: Britecyte positions early intervention (during active weight loss) as advantageous — rebuilding substrate before the deficit becomes severe. Surgeons should confirm per the full IFU whether the patient's current GLP-1 use affects the integration protocol.

Note on IFU: Britecyte's prescribing information. Active GLP-1 use is not a contraindication — most providers treat patients during active GLP-1 therapy. Review the full contraindication and precaution list before treating. This summary does not replace the IFU.

Author: Dr. William Gregory Chernoff, BSc, MD, FRCSC — triple board-certified facial plastic and reconstructive surgeon (American Board of Facial Plastic and Reconstructive Surgery; American Board of Otolaryngology–Head and Neck Surgery; Royal College of Physicians and Surgeons of Canada). Fellowship training at UCSF. 30+ years clinical experience.

Study design: Six-month proof-of-concept study with concurrent safety evaluation. IRB-approved (IRB ICSS-2021-011). 12 patients (8F / 4M), ages 32–76 (mean 42 years), all on GLP-1 therapy ≥1 year. Implantation volumes 1–10cc per session. Assessment by 2D photography and Quantificare 3D imaging. Patient satisfaction via visual analog scale.

Sites treated: Malar/submalar, nasolabial and melolabial folds, nasal dorsum, lower third of face, pre-jowl sulcus, tear trough, upper eyelid, hands, breasts, buttocks, legs. Also used in multimodal wound and scar management protocols.

Follow-up: Daily for 1 week → weekly for 1 month → monthly through 6-month endpoint.

Skin quality: Quantificare 3D imaging demonstrated measurable improvement in skin tone, texture, and overall skin quality when Lipoderma was implanted in the immediate subdermal plane. Improvement was particularly noted in atrophic scars, striae, and cellulite, where restoration of structural adipose support improved tissue quality.

Volume retention: Where volumization was the primary goal, Quantificare analysis demonstrated successful early outcomes with sustained volume retention through the six-month endpoint.

Hybrid protocols: In select cases, Lipoderma was combined with hyperdilute calcium hydroxyapatite (CaHA) for larger-area body volumization (medial thigh, gluteal region). These hybrid approaches appeared to enhance clinical effectiveness. One patient (74-year-old female, posterior gluteal, two sessions) was followed to 12 months with continued documented improvement.

Wound and scar application: When incorporated into multimodal wound or scar protocols, Lipoderma helped supplement the missing hypodermal adipose layer, with observed improvements in atrophic scars, striae, and cellulite.

Safety: Zero adverse events. No allergic reactions, no hypersensitivity responses, no other adverse events attributable to Lipoderma at any study timepoint across all 12 patients.

Chernoff's framing is directly aligned with the dWAT-restore-first clinical rationale: "By restoring the structural adipose layer beneath the dermis, [Lipoderma] offers a like-for-like solution for areas where native adipose tissue has been diminished or lost."

On the significance of dWAT: "As understanding of dWAT continues to evolve, restoration of this layer is increasingly recognized as an important component of maintaining skin integrity and structural support. Re-establishing the adipose layer helps recreate the physiologic environment necessary for normal dermal function."

On the category shift Lipoderma represents: "This restoration-based strategy may represent an important shift in aesthetic and reconstructive medicine — from simply replacing lost volume to rebuilding the structural tissue layers that support skin health."

Chernoff also explicitly positions autologous fat transfer as the only previously recognized approach capable of restoring adipose tissue layers — and frames Lipoderma as the off-the-shelf alternative that removes the donor site requirement.

Published references cited by Chernoff: Chen et al. J Invest Dermatol 2019 (dWAT innate defense); Paschou et al. Endocrine 2025 (GLP-1 and skin aging); Ridha et al. Aesthet Surg J 2024 (GLP-1 and facial aging); Rosenbloom et al. Aesthet Surg J Open Forum 2025 (GLP-1 and aesthetic medicine); Sataray-Rodriguez et al. J Biomed Sci Eng 2025 (GLP-1 fat loss and collagen/elasticity).

Donor fat insufficiency is a hard anatomical constraint in fat transfer surgery — particularly in lean patients, post-bariatric patients, and GLP-1 users. When donor volume falls short, the intraoperative options are limited: under-correct, harvest from a secondary site with associated morbidity, or schedule a staged return procedure.

Lipoderma as intraoperative supplement: Its ~90/10 adipocyte/ECM composition allows co-injection alongside autologous fat into the same recipient site with no compositional discontinuity. The result is a combined volume that does not require a second procedure. Consistent delivered volume per vial — independent of patient donor site quality, harvesting technique, or centrifugation variability.

Post-resorption touch-up: Lipoderma can be used as an office-based injectable 6–12 months post-transfer when resorption has been higher than planned. The recipient site is already vascularised and the correction need is discrete. No HA filler provides an architecturally matched result in this setting.

Facial fat grafting requires small-volume, multi-compartment injection. In patients with very low body fat — GLP-1 users, post-bariatric patients, elderly — available donor volume often cannot address all target compartments in one session. Lipoderma extends this reach without a second harvest.

Britecyte's clinical documentation includes a 36-year-old female with reduced facial fat pads secondary to weight loss, treated with Lipoderma for midface and jawline restoration with before/after imaging at 12 months, and a 22-year-old female with severe acne scarring treated bilaterally in the malar and submalar regions. Manufacturer-documented cases with imaging — not peer-reviewed.

vs. ECM-only scaffolds: Renuva and Leneva contain no adipocytes and provide no immediate volume. For patients requiring immediate correction alongside biological integration, Lipoderma is the only off-the-shelf option providing both.

Regulatory: Lipoderma (Liposana™, Britecyte, Inc., Frederick, MD) is regulated as an HCT/P under Section 361 of the Public Health Service Act and 21 CFR Part 1271 — the same pathway as allogeneic skin grafts and corneal tissue. Not a drug, not a 510(k) device. Does not require the Phase I–III clinical trial pathway. Manufactured by LifeLink Foundation, Inc. (Tampa, FL) — AATB-accredited, FDA-registered, licensed in FL, CA, MD, and NY.

Storage: Cryopreserved. Refrigerated storage at 0–10°C: 12-month shelf life. Ships refrigerated. Allow 30–60 minutes to reach room temperature before use — use within 4 hours of reaching room temperature. Cold chain applies from receipt through patient use. Do not freeze.

Injection: Flowable consistency. Injectable through standard needle gauges used in fat transfer and filler procedures. No specialised equipment required. Available in 1.5cc (facial) and 10cc (body) formats.

Adverse event profile: No adverse events across three clinical datasets: Regulski et al. 2024 (n=12); Schoenhaus Gold et al. 2025 (n=9 patients / 10 feet); Chernoff 2025 (n=12 GLP-1 patients, facial and body sites, 6-month follow-up, IRB ICSS-2021-011). No detectable anti-CAT antibodies in rat immunogenicity model at 4 weeks. Small cohorts, limited follow-up — longer-term data ongoing.

Contraindications: Hypersensitivity to allogeneic tissue. Active GLP-1 use is not a contraindication — work with your patient on when best to incorporate Lipoderma into their GLP-1 journey. Full contraindication, warning, and precaution list in Britecyte prescribing information — this summary does not replace it.